CEO @generate_biomed and CEO/Partner @FlagshipPioneer. Passionate about working with teams and partners to bring innovations to patients. My posts are my own.
Joined July 2012
- Tweets181
- Following213
- Followers1K
- Likes1.2K
Mike Nally retweeted
What will drug discovery look like when intelligence is abundant?
Our team at @generate_biomed began with this question, and we’re excited to share some results!
We took on in vivo CAR-T and designed a scaffold 70% smaller than ones in the clinic, with 3x the potency 🧵
Making medicines is really hard. Excited to share some early work from the team @generate_biomed with our partners @AnthropicAI on how we can leverage agentic tools to rapidly advance science. While it is still early days, the signals are very promising and patients are waiting.
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own.
In doing so, we’ve learned much more about how Claude can support the many stages of drug development.
In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences.
anthropic.com/research/early…
Proud of the work our team @generate_biomed is doing to help patients with COPD.
GB-0895, our anti-TSLP monoclonal antibody, has entered a Phase 1 clinical trial for chronic obstructive pulmonary disease (COPD)—its second indication following asthma. Designed using generative optimization, GB-0895 was built for high potency, extended half-life, and targeted function.
This is the fourth clinical trial for a molecule designed on our platform and reflects how generative optimization can produce antibodies with defined therapeutic properties that advance efficiently into clinical development.
Learn more: lnkd.in/eEpPjrTF
Mike Nally retweeted
GB-0895, our anti-TSLP monoclonal antibody, has entered a Phase 1 clinical trial for chronic obstructive pulmonary disease (COPD)—its second indication following asthma. Designed using generative optimization, GB-0895 was built for high potency, extended half-life, and targeted function.
This is the fourth clinical trial for a molecule designed on our platform and reflects how generative optimization can produce antibodies with defined therapeutic properties that advance efficiently into clinical development.
Learn more: lnkd.in/eEpPjrTF
Always great to catch up with @ChristineHeenan and share how our team @generate_biomed is leveraging the best of human and machine intelligence to learn from nature to make breakthrough medicines. We are in the early days of programmable biology and the future is bright.
From the #FlagshipStudio: @generate_biomed CEO @mike_nally explains how Generate is a case example of the power of polyintelligence as it brings together human, machine, and nature’s intelligence to pioneer generative AI technologies in biology. Catch the full CEO Chat for more on Generate’s expanding pipeline of programs and partnerships, including with @Amgen, @Novartis, and others: bit.ly/4anyOE1
#JPM25
Generative technologies have the potential to materially improve the standard of care for patients in a number of domains. GB-0895 is a great example of how our team at @generate_biomed is focused on getting better medicines to patients, faster.
This quoted post is unavailable.
Mike Nally retweeted
A vaccine has essentially eliminated a dreadful form of cancer.
Extraordinary.
Scotland has detected no cases of cervical cancer in women born between 1988-1996 who were fully vaccinated against HPV between the ages of 12 and 13.
statnews.com/2024/01/25/hpv-…
Mike Nally retweeted
How do AI & drug development expertise reshape what’s possible? In a multi-target collaboration potentially valued at over $1 billion, we are partnering with @Novartis to develop novel protein therapeutics that address critical medical needs. Learn more: generatebiomedicines.com/new…
Mike Nally retweeted
Last night on @60Minutes, Alex Snyder, MD, our EVP of R&D, sat down with @BillWhitakerCBS to share our patient-first approach to healthcare: “We’re pushing the biology to make drugs that look like regular drugs, but function even better.” Watch here:
Researchers are using AI to create new proteins that do not exist in nature to fight diseases like cancer and asthma. cbsn.ws/3Qp03FL
Mike Nally retweeted
Researchers are using AI to create new proteins that do not exist in nature to fight diseases like cancer and asthma. cbsn.ws/3Qp03FL
The biotech brackets are out and a Cinderella story emerging with @generate_biomed as a #13 seed. nam12.safelinks.protection.o…
Mike Nally retweeted
Join Grace Marden, one of our infectious disease scientists, at @IAS_USA's CROI to hear about our groundbreaking antiviral research. Can’t attend? Check out the video below to see how we are using AI to ensure we are prepared for future pandemics.
Mike Nally retweeted
Advances in artificial intelligence are at the heart of many of this year’s most exciting areas of technological innovation go.nature.com/48Zri0o
Mike Nally retweeted
Hear CEO of @generate_biomed Mike Nally share updates on Generate:Biomedicines and why the company may have the Mona Lisa of molecules when it comes to treating mild-to-moderate asthma. Catch his full CEO Chat here: flagshippioneering.com/stori… #FlagshipJPM #JPM24
Unfortunately, cancer is personal for most of us. We are delighted to be partnering with one the preeminent cancer centers in MD Anderson Cancer Center to bring the power of generative AI to the fight against this disease.
Through our new collaboration with @MDAndersonNews, we aim to harness the power of The Generate Platform to create optimized, potentially best-in-class oncology therapeutics that can rapidly advance into proof-of-concept trials. Learn more: generatebiomedicines.com/new…
Really enjoyed sitting down with @ChristineHeenan from @FlagshipPioneer to discuss how @generate_biomed is striving to bring better medicines to patients faster, including the critical role that culture plays in our success.
Mike Nally, CEO of @generate_biomed, explains how the company is leveraging computation to accelerate the pace of drug discovery and development. More from his interview at #JPM23 here: bit.ly/MikeNally #FlagshipJPM
Mike Nally retweeted
Very exciting future for #proteindesign and #AI! Congratulations to @generate_biomed on making the future possible. #Proteins are where life work gets done, and now we can make new ones.
Today we introduced Chroma, a generative model that creates new proteins & protein complexes given geometric & functional constraints. It learns to transform unstructured, random 3D shapes into #protein molecules, which can have tens of thousands of atoms. ow.ly/Txn750LShFp
Our co-founder @gibsmk shares how we are increasingly making biology engineerable @generate_biomed. We believe this will have a transformative impact on the patients we serve. Thanks Lydia The for highlighting our work.
#DYK there is a 90% failure rate in drug development? Our Co-Founder and CIO, @gibsmk, shares how with #AI we are no longer predicting biology, but rather generating new biology which will help us develop faster, better, and more affordable therapeutics: mck.co/3tJeW9S
I am excited to join @DianaBrainard, @AlexHoos, @SheilaMikhail, @PascalTouchon and @AnnalisaDAndrea this Thursday for an exciting discussion on advancing platform technologies @longwoodleaders.
Mike Nally retweeted
Proud of our colleagues Alexandra Snyder & Dinesh De Alwis for their commentary published today in @NatureMedicine on the impact of clinical holds on smaller biotechs and how they ultimately benefit patients by leading to better medicines. ow.ly/mFsb50KM1BR
